Halving Time of BCR-ABL1 in Chronic Myeloid Leukemia: Is It Better Than Day-90 Value—A Multicenter Study From South India

Shashidhar V. Karpurmath, Arun Seshachalam, Kalaiselvi Selvaraj, Priyadarshini Rajamani, Satish kumar, Neelesh Reddy, Baswant Malipatil, Roopa Sirigeri, Krishna Prasad, Krishna Reddy, Madhav Danthala, Karthik S. Udupa, Manjunath Nandennavar, Janarthinakani Murugesan, C. N. Patil, Parameswaran Anoop, Roshan Koshy Jacob, Mallikarjun Kalashetty, Krishnakumar Rathnam, Ramanan Ganapathy

Research output: Contribution to journalArticle

Abstract

We found that the rate of decline of BCR-ABL1 (breakpoint cluster region-Abelson 1) is a better predictor of the molecular response in patients with chronic myeloid leukemia than the single 90-day value. The present retrospective cohort study of 90 patients is the first study in the Indian context comparing the rate of decline of BCR-ABLl against the single 90-day value.

Original languageEnglish
JournalClinical Lymphoma, Myeloma and Leukemia
DOIs
Publication statusAccepted/In press - 01-01-2020

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Cite this